摘要:
The present invention relates to the treatment and prophylactic prevention of Alzheimer's disease. More specifically, the present invention relates to methods and compositions for reducing production of β amyloid by reducing or preventing the binding of amyloid precursor protein (APP) to an X11 adaptor protein. Also provided are methods for identifying molecules that modulate APP-X11 binding.
摘要:
Disclosed herein is a method for administering compositions. Also disclosed are kits comprising a compound of formula (I) to (V), or an enantiomer, an analog, a derivative, an isomer, prodrug, or a pharmaceutically acceptable salt thereof, for use in temporal proximity to anesthesia. The methods, compositions and kits provided herein can be used for reducing anesthesia-induced neurotoxicity and post-operative cognitive dysfunction (POCD) in a subject.
摘要:
The present invention is directed to isolated amyloid precursor-like proteins (APLPs), nucleotide sequences coding for and regulating expression of these protein, antibodies directed against these proteins, and recombinant vectors and host cells containing the genetic sequences coding for and regulating the expression of these protein sequences. The invention is also directed to isolated genomic DNA, cDNA anti-sense RNA, and RNA containing the protein sequence. Antibodies can be used to detect an APLP in biological specimens, including, for example, fluid, serum or tissue samples. APLP1 and APLP2 are candidate genes for late onset familial Alzheimer's disease.
摘要:
The invention relates to methods for identifying candidate pharmacological agents to be used in the treatment and/or prevention of Alzheimer's disease and/or related pathological conditions.
摘要:
The present invention is directed to isolated amyloid precursor-like proteins (APLPs), nucleotide sequences coding for and regulating expression of these protein, antibodies directed against these proteins, and recombinant vectors and host cells containing the genetic sequences coding for and regulating the expression of these protein sequences. The invention is also directed to isolated genomic. DNA, cDNA anti-sense RNA, and RNA containing the protein sequence. Antibodies can be used to detect an APLP in biological specimens, including, for example, fluid, serum or tissue samples. APLP1 and APLP2 are candidate genes for late onset familial Alzheimer's disease.
摘要:
Disclosed herein are novel methods, assays and systems for detecting an increased risk for Alzheimer's disease (AD) in a subject by identifying at least one nuclei acid polymorphism described herein in a biological sample from the subject. Levels of the genes associated with the nucleic acid polymorphism described herein are also determined for detection of higher risk for AD. Disclosed herein further provides methods for treating AD by administering to a subject in need thereof with ATXN1.
摘要:
The invention relates to antibodies that bind cross-linked amyloid β oligomers, and methods for using such antibodies for diagnosis and treatment of Alzheimer's disease.
摘要:
Isolated nucleic acid molecules are provided encoding human PS1 gene products. Mutant PS1 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of the activity of the PS1 polypeptide and mutants thereof. Also provided are diagnostic methods for detecting Alzheimer's disease and therapeutic methods for treating the same.
摘要:
The invention relates to the identification of clioquinol as a pharmaceutically therapeutic agent for treatment of Alzheimer's disease and related pathological conditions.
摘要:
The invention relates in part assays for identifying and testing compounds that modulate cleavage of amyloid precursor protein (APP). In addition, the invention relates to novel cleavage products of APP. The invention additionally relates to methods and assays for identifying compounds that inhibit acyl-coenzyme A:cholesterol acyltransferase (ACAT) activity. The methods and products of the invention are useful for identifying compounds to prevent and/or treat APP-cleavage associated disorders (e.g. Alzheimer's disease) and are also useful for identifying compounds to prevent and/or treat ACAT-associated disorders.